{"url_path":"/sec/rxst/8-k/2026-07-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1111485/0001193125-26-304812-index.html","accession_number":"0001193125-26-304812","cik":"0001111485","ticker":"RXST","issuer_name":"RxSight, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1111485/0001193125-26-304812-index.html","primary_entity_key":"0001111485","primary_entity_name":"RxSight, Inc."},"word_count":141,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn July 15, 2026, the Company issued a press release announcing the appointment of Mr. Mottiwala as President and Chief Executive Officer of the Company and the transition of Dr. Kurtz to Chief Medical Officer. A copy of the press release announcing such information is furnished herewith as Exhibit 99.1 and incorporated by reference into this Item 7.01 by reference.\n\nThe information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such filing."}